Table 1.

Demographic information by study cohort

Cohort	Age first visit, μ (SD)	N Males/N Females	Follow-up years, μ (SD)	Change in GCP*, μ (SD)	Change in MMSE* μ (SD)	λ† GEE‡	λ LME§
3C	77.9(5.6)	139/216	6.5(2.5)	2.8(4.5)	2.1(3.6)	1.06	1.36
ACT	78.2(6.1)	68/106	7.7(2.8)	4.1(5.4)	1.40(.9)	1.45	1.16
AddNeuroMed	77.3(6.8)	110/179	1.2(1.0)	1.5(4.9)	1.9(3.9)	1.15	3.25
ADNI	75.7(6.4)	157/115	2.7 (1.4)	4.8 (5.1)	2.4(4.6)	1.11	3.18
Flurizan	74.6(8.2)	548/533	1.2(0.6)	2.2(7.1)	3.6(5.0)	1.05	2.26
NACC	78.3(7.9)	271/268	2.2(1.7)	6.2(6.2)	1.8(3.8)	1.10	2.14
Pfizer	75.7(5.0)	69/92	1.5(2.5)	2.5(4.3)	2.0(3.6)	1.06	2.31
ROS/MAP1	82.4(6.5)	120/262	7.9(4.5)	4.5(7.0)	1.1(3.5)	1.08	3.23
ROS/MAP2	82.6(7.7)	24/55	1.4(.5)	3.5(5.8)	0.9(3.3)	1.28	2.94
Semagacestat	74.1(7.7)	152/155	1.3(.5)	1.5(4.9)	2.6(4.4)	1.08	10.37
WashU	74.2(7.5)	110/129	5.7(4.9)	2.9(4.9)	1.5(3.3)	1.14	5.37
WHICAP	82.3(7.9)	20/48	5.0(3.5)	1.1(6.1)	1.7(3.8)	3.42	1.63

^*during the first two years of follow up post AD diagnosis,

^†genomic inflation factor,

^‡Generalized Estimating Equations,

^§Linear Mixed Effects